The feasibility of using preparations of cell-free, fibrous dermal collagen, prepared by trypsin-treatment of skin, for the repair of soft body tissues has been examined both as subcutaneous implants and as a replacement for dermis in skin wounds in rats. Increased collagen stability, and suppression or reduction of tissue antigenicity in collagen heterografts, was achieved by crosslinking with weak solutions of aldehydes while still allowing implant recellularization and revascularization. Tritium-labelled collagen turnover studies have shown that maintenance of collagen mass in implants crosslinked with glutaraldehyde occurs primarily by inhibition of loss of original implant collagen. Some of the in vitro growth characteristics of human fibroblasts on animal collagen preparations are also described.